Department of Health and Human Services, through National Institutes of Health, awarded Jillion Therapeutics Inc. of Brooklyn, NY $399,483 under the SBIR program (Phase I), with work starting 2025-05-15 and running to 2027-04-30. It is one of 2 SBIR and STTR awards Jillion Therapeutics Inc. received in the last two years, $797,576 in all. Each figure links to the federal record.
The award
| Recipient | Jillion Therapeutics Inc. (Brooklyn, NY) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $399,483 |
| Period of performance starts | 2025-05-15 |
| Period of performance ends | 2027-04-30 |
| Award number | R43DA062975 (grant, CFDA 93.279) |
| Assistance listing | 93.279, Drug Use and Addiction Research Programs |
| Signed | 2025-05-07 |
| Recipient registry id (UEI) | KNVYBLASYW88 |
Want the whole picture on Jillion Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Jillion Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jillion Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Synergy between artificial intelligence and dna-encoded library technologies to identify polypharmacological therapeutics for substance use disorders - project summary synergy between artificial intelligence and dna-enco
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-04-08 | Revision | 000 | $0 |
| 2025-05-07 | New | 000 | $399,483 |
Synergy between artificial intelligence and dna-encoded library technologies to identify polypharmacological therapeutics for substance use disorders - project summary synergy between artificial intelligence and dna-encoded library technologies to identify polypharmacological therapeutics for substance use disorders the objective of this Phase I SBIR project is to generate synergy between artificial intelligence (AI) and our own innovative and proprietary dna-encoded library (del) drug discovery platform to identify novel multivalent compounds relevant for suds. Each technology complements the other extremely well. The overreaching goal is to restore, with one compound, complex brain functions impacting two, and possibly 3, important pathways. Suds, result from the imbalance of opioid and dopaminergic pathways affecting the reward system, the mesocorticolimbic dopaminergic system in particular, leading to long-lasting rewiring of the brain, and involving the brain default-mode network. We have extensively studied numerous relevant pathways, and the basal ganglia signaling in general, in the greengard lab. We will identify molecules that target “2+1” neurotransmitter systems: 2 immutable systems are the opioid and dopaminergic systems to reduce cravings and withdraw symptoms while addressing reward; 1 accessory system will be the serotonergic system to address emotional and psyc ...
From the federal award record.
Other SBIR and STTR awards to Jillion Therapeutics Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-07-01 | Department of Health and Human Services | SBIR Phase I | $398,093 | Identification of therapeutic molecules to treat amphetamine use disorders using our dna-e (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Jillion Therapeutics Inc.Look up Jillion Therapeutics Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.